Biogen Inc., incorporated on April 1, 1997, is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The Company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies.
The Company's TECFIDERA (dimethyl fumarate) is an oral therapy approved in the United States for the treatment of relapsing MS. TECFIDERA has been proven to reduce measures of disease activity, including relapses and development of brain lesions, as well as to slow disability progression over time. TECFIDERA is also approved in Canada, Australia, Switzerland and the European Union. PLEGRIDY (peginterferon beta-1a) is approved for the treatment of relapsing forms of MS with a dosing schedule of once every two weeks. AVONEX is approved for the treatment of patients with relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. AVONEX should be used with caution in patients with depression or other mood disorders and in patients with seizure disorders. PLEGRIDY contains interferon beta-1a, which is pegylated to extend its half-life. TYSABRI (natalizumab) is a treatment approved for relapsing forms of MS in adults in the United States and active relapsing-remitting MS in adults in the European Union. ZINBRYTA (daclizumab) is approved in the United States for the treatment of relapsing forms of MS. FAMPYRA (prolonged-release fampridine tablets) is a treatment indicated to improve walking in adult patients with MS. The Company offers BENEPALI to treat moderate to severe rheumatoid arthritis; progressive psoriatic arthritis; axial spondyloarthritis, and moderate to severe plaque psoriasis.
The Company's product candidates include OCREVUS; Biosimilar adalimumab; GAZYVA; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; rAAV-XLRS; BG00011 (STX-100); Dapirolizumab pegol; BIIB059; BIIB061; BIIB054; BIIB067, and BIIB068. In addition, the Company is also engaged in developing late stage product candidates, including programs in Phase III development or in registration stage. Its late stage product candidates include Aducanumab (BIIB037), E2609, Adalimumab (SB5), GAZYVA (obinutuzumab) and OCREVUS (ocrelizumab).
The Company competes with Sanofi, Bayer Group, Teva Pharmaceuticals Industries Ltd., Novartis AG and Merck KGaA.